Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

A new study analyzed how often people develop severe side effects after taking semaglutide — known by brand names Ozempic and ...

The pharmaceutical firm Novo Nordisk is pursuing a multi-pronged strategy to regain market share that it has lost to Eli ...

But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

CVS Health's pharmacy benefits manager said weight-loss drugs from rival drugmaker Novo Nordisk will become the preferred ...

The DOJ alleges in its complaint that CVS Health-unit Aetna, Elevance Health and Humana paid the kickbacks to brokers eHealth, GoHealth and SelectQuote in exchange for enrollments into the insurers' ...

Starting on July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

The Council for Innovation Promotion tracks counterfeits in a lot of industries, but when it comes to consumer safety, Cullen ...

Though popular weight loss jabs like Ozempic and Wegovy have been deemed safe and effective by the FDA, concerning side effects are sending some users to the ER.

CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.